Sysmex (OTCMKTS:SSMXY) Sees Large Volume Increase – Time to Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares saw unusually-strong trading volume on Monday . Approximately 1,025,127 shares changed hands during mid-day trading, an increase of 478% from the previous session’s volume of 177,212 shares.The stock last traded at $9.96 and had previously closed at $9.84.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upgraded shares of Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Sysmex Stock Up 0.8%

The firm’s fifty day simple moving average is $10.01 and its 200 day simple moving average is $12.77. The company has a current ratio of 3.34, a quick ratio of 2.49 and a debt-to-equity ratio of 0.11. The company has a market cap of $6.24 billion, a price-to-earnings ratio of 19.83 and a beta of 1.13.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Wednesday, November 5th. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $826.60 million during the quarter, compared to the consensus estimate of $880.80 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. Sell-side analysts predict that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.